# Neuphoria Therapeutics Inc. (NEUP) FY2026 Annual Balance Sheet

- Company: Neuphoria Therapeutics Inc. (NEUP)
- Period: As of 2026-06-30
- Filing: FY2026 10-K, filed 2026-09-18, accession number 0001193125-26-395536
- Page: https://plicit.ai/financials/neup/fy2026-annual-balance-sheet
- Chart image: https://plicit.ai/charts/neup-fy2026-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 28,709,016 US dollars
- **Current assets**: 21,068,734 US dollars
- **Non-current assets**: 7,640,282 US dollars
- **Liabilities**: 4,108,994 US dollars
- **Current liabilities**: 756,581 US dollars
- **Non-current liabilities**: 3,352,413 US dollars
- **Equity**: 24,600,022 US dollars
- **Cash and cash equivalents**: 19,865,531 US dollars
- **Accounts receivable, non-trade**: 813,431 US dollars
- **Prepaid expenses**: 389,772 US dollars
- **Intangible assets, net**: 4,142,060 US dollars
- **Goodwill**: 3,498,222 US dollars
- **Accounts payable**: 385,584 US dollars
- **Accrued expenses and other current liabilities**: 370,997 US dollars
- **Accompanying warrant liability**: 1,971,172 US dollars
- **Contingent consideration**: 1,025,301 US dollars
- **Deferred tax liability**: 355,940 US dollars
- **Additional paid in capital, net of subscription receivable**: 218,461,772 US dollars
- **Common stock, $0.00001 par value, 5,411,334 and 1,978,460 shares issued and outstanding at June 30, 2026 and 2025, respectively**: 54 US dollars
- **Accumulated deficit**: negative 191,798,634 US dollars
- **Accumulated other comprehensive loss, net of tax**: negative 2,063,170 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.